Document:

EX-10.1.2

 Exhibit 10.1.2 

CONFIDENTIAL TREATMENT REQUESTED BY CELLECTIS S.A.—CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE
COMMISSION. 
 AMENDMENT NO. 2 TO THE PATENT LICENSE AGREEMENT NO. C-00061901 

BETWEEN: 
 L’Institut Pasteur, a public
interest foundation, 25, rue du Docteur Roux, 75015 Paris, represented by Mr. Jean Castex, adjunct General Manager for administration and finance, and by Mr. Christian POLICARD, Director of Business Development and Industrial Partnerships.

 Hereafter referred to as “IP” or the “LICENSOR”, acting both on its own behalf and on behalf of: 

 

	•	 	Université Pierre et Marie Curie, 

 4, place de Jussieu, 

75252 Paris cedex 05, 
 Hereafter
referred to as “UPMC”, 
  

	•	 	Institut Curie,  

 26, rue d’Ulm, 

75248 Paris cedex 05, 
 Hereafter
referred to as “IC”, 
  

	•	 	Le Centre National de la Recherche Scientifique, 

 3, rue Michel-Ange, 

75794 Paris cedex 16 
 Hereafter
referred to as “CNRS”. 
 Jointly also referred to as the “LICENSOR”, 

Party of the first part, 
 AND: 

CELLECTIS, a public limited company with a capital of 122,363.47 euros, headquartered at 28, rue du Docteur Roux, 75724 Paris cedex 15, represented by
Mr. André Choulika, acting as Chief Executive Officer 
 Hereafter referred to as “CELLECTIS” or the “LICENSEE”, 

Party of the second part. 
 The LICENSOR and LICENSEE are
hereafter referred to as the “Parties”. 
 RECITALS: 

IP is the co-owner, along with UPMC, IC and CNRS, of patents and patent applications related to the gene of the I-Sce I enzyme, the expression of the
I-Sce I enzyme and its use. 
 UPMC, IC and CNRS have empowered IP, who accepts this, to represent them and negotiate in their name any license
agreement with CELLECTIS and any amendments thereto. 

 On June 19, 2000, the Parties signed licensing agreement no. C-00061901 (hereafter “the
AGREEMENT”) in which the LICENSOR grants the LICENSEE operation rights to the patents and patent applications mentioned above. 
 Following discussions
and exchanges between the Parties, they determined that it would be useful to modify the provisions of the AGREEMENT. 
 It is thus agreed as follows:

 ARTICLE 1 
 1.1 The Parties agree that
the words defined in Article 1, “DEFINITIONS”, of the AGREEMENT, as they are used in this amendment, have the same definitions as in the AGREEMENT and form an integral part of this amendment. 

1.2 The following definitions apply for the purposes of this amendment, it being understood when permitted by context that the singular shall be considered to
include the plural and vice versa: 
  

	 	1.2.1	By “I-SceI and/or I-Spom I” the Parties agree to mean the technologies claimed by the AGREEMENT PATENTS of LICENSE AGREEMENT no. C-00061901 signed between the Parties. 

 

	 	1.2.2	By “PGN”, the Parties agree to mean the technologies claimed by AGREEMENT PATENTS of LICENSE AGREEMENT no. C-00061906 signed between the Parties. 

 

	 	1.2.3	By “Mulligan”, the Parties agree to mean the technologies claimed by the AGREEMENT PATENTS of LICENSE AGREEMENT no. C-00061905 signed between the Parties. 

 

	 	1.2.4	For the sole purposes of Articles 3.4 and 3.5 as modified by this amendment, the word “TOOL” will have the definition stated below: 

By “Tool”, the Parties agree to mean the use by the Licensee’s sub-licensee of the LICENSED PROCESSES or LICENSED PRODUCTS for
internal purposes or as part of the research or development process conducted by the sub-licensee. 
 ARTICLE 2 

Article 2.4 of the AGREEMENT is modified by the following provisions, which supersede all previous provisions of that same article: 

 

	“2.4	The LICENSEE may only grant sub-licenses to third parties for the rights which it receives under this Agreement with the prior AGREEMENT of the LICENSOR. If the LICENSOR does not communicate its disagreement within
twenty-one days from the notification of a sub-licensing project, it shall be considered to have agreed. 

 The LICENSOR may
refuse to grant prior agreement for a sub-license only for serious cause. 

 The following would constitute serious cause justifying IP’s refusal to agree: a
sub-licensing agreement between the LICENSEE and a THIRD PARTY containing provisions which are contrary to the ethics, image or intellectual property of the LICENSOR.” 

ARTICLE 3 
 Article 3.4 of the AGREEMENT is
modified by the following provisions, which supersede all previous provisions of the same article: 
  

	“3.4.1	For sub-licenses concerning a LICENSED PATENT for the use of TOOLS granted by the Licensee under Article 2.4 of this Agreement, the LICENSEE will pay the LICENSOR [***] of any compensation it receives, lump sums,
royalties, market values (for cross-licensing or exchanges) for all sub-licenses granted to THIRD PARTIES.” 

  

	3.4.2	For sub-licenses concerning LICENSED PATENT other than those mentioned in Article 3.4.1 above, granted by the Licensee under Article 2.4 of this AGREEMENT, the LICENSEE will pay to the LICENSOR [***] of any compensation
it receives, lump sums, royalties, market values (for cross-licensing or exchanges) for all sub-licenses granted to THIRD PARTIES, excluding the amounts stipulated in Article 3.5, without the amount of the royalties owed to the LICENSOR being less
than: 

  

	 	•	 	[***] of the net revenues of the sub-licensee for the ISCEI and/or I-Spom I technologies, Mulligan and PGN granted together to the same sub-licensee 

 

	 	•	 	[***] of the net revenues of the sub-licensee for ISCEI and/or I-Spom I technologies granted alone or with Mulligan to the same sub-licensee. 

ARTICLE 4 
 Article 3.5 of the AGREEMENT is
modified by the following provisions, which supersede all previous provisions of the same article: 
  

	“3.5	The sub-licensees of the LICENSEE, falling into the category of sub-licensees under article 3.4.2, for each sub-licensing agreement signed, will be required to pay an amount of [***] which will be passed on in full to
the LICENSOR as patent fees already incurred. These same sub-licensees must also pay an amount of [***] each year, which will be passed on to the Licensor as patent fees. 

The LICENSEE’s sub-licensees, falling into the category of sub-licensees under article 3.4.1, will not be required to pay any amount as
patent fees. 
 ARTICLE 5 
 The last sentence of
article 10.1 par. 2 § is modified as follows: 
 “This share must not be less than [***] per year.” 

 
 [***] CONFIDENTIAL MATERIAL REDACTED AND SEPARATELY FILED WITH THE COMMISSION.

 ARTICLE 6 

Article 2.6 of the licensing Agreement is modified by the following provisions, which supersede all previous provisions of the same article: 

“The IMPROVEMENTS achieved by the LICENSOR are exclusively licensed to the LICENSEE for a period of 5 (five) years following the date of signature of
Amendment no. 2 to this AGREEMENT. 
 “The LICENSOR will inform the LICENSEE of the existence and contents of the IMPROVEMENTS. 

“Following the 5 (five) year period, the Parties will come together to mutually agree on the terms of access to the IMPROVEMENTS.” 

ARTICLE 7 
 The last sentence of article 1.5 of the
Agreement is modified as follows: 
 “Patents filed to protect IMPROVEMENTS will be included in the AGREEMENT PATENTS in accordance with the provisions
of article 2.6 of this AGREEMENT.” 
 ARTICLE 8 

This amendment will enter into force on the date of its signature. 

The Agreement’s other provisions remain unchanged and in force between the Parties. 

 

					
	 Signed in Paris on
 in 2 original
copies.
		[Handwritten text: September 8, 2003]		

					
			
	CELLECTIS				INSTITUT PASTEUREX-10.1.3

 Exhibit 10.1.3 
  

			
	Avenant au contrat de licence de brevet N° C-00061901		Amendment to License contract # C-00061901
		
	 L’Institut Pasteur,
 Fondation
reconnue d’utilité publique ayant son siège au 25-28, rue du Docteur Roux, ci-après dénommée « LE DONNEUR DE LICENCE »
		 lnstitut Pasteur, located at 25-28 rue du Docteur Roux - 75724 Paris Cedex 15- France (hereinafter the « Licensor
»)

		
	Représenté par le Pr. Alice DAUTRY, Directrice Générale,		Represented by Pr. Alice DAUTRY, President,
		
	et		and
		
	Cellectis, Société Anonyme inscrite au Registre du Commerce etdes Sociétés de Bobigny sous le n° 428 859 052, ayant son siège au 102 avenue Gaston Roussel - 93235 Romainville, ci
après dénommée « LE PRENEUR DE LICENCE »		Cellectis, a company organized and existing under the laws of France, registered under the Registre du Commerce et des Sociétés of Bobigny under n° 428 859 052, located at 102 avenue Gaston Roussel - 93235
Romainville - France (hereinafter the « Licensee >>)
		
	Représentée par M. André CHOULIKA, Directeur Général		Represented by Mr Andre CHOULIKA, Chief Executive Officer,
	  
 Préambule
		  
 Recitals

		
	Le DONNEUR DE LICENCE est une fondation reconnue d’utilité publique, ayant pour objet la recherche dans le domaine de la santé.		Licensor is a charity foundation dedicated to research in the field of human health.
		
	En sa qualité de co-propriétaire des BREVETS DU CONTRAT, mandaté par les co-propriétaires l’Université Pierre et Marie Curie, l’Institut Curie et le Centre Nationale de la Recherche
Scientifique pour les représenter et négocier en ieur nom tout contrat de licence avec le PRENEUR DE LICENCE, LE DONNEUR DE LICENCE a concédé une licence exclusive au PRENEUR DE LICENCE le 19 juin 2000, jointe au
présent avenant, ci après « LE CONTRAT DE LICENCE ».		As co-owner of the Agreement Patents, empowered by the co-owners Universtité Pierre et Marie Curie, lnstitut Curie and Centre National de la Recherche Scientifique to represent them and negotiate in their names any license
agreement with Licensee, Licensor has executed an exclusive license with Licensee on June the 19th 2000, as attached to the present amendment, hereafter “the Agreement”.
		
	Le 27 Décembre 2007, en applications des dispositions contenues au paragraphe 7.3 du CONTRAT DE LICENCE, le DONNEUR DE LICENCE et le PRENEUR DE LICENCE, après consultation mutuelle, ont décidé que les
poursuites contre la société Précision Biosciences Inc (ci-après « LE CONTREFACTEUR ».), située au 104 T.W. Alexander Dr., Bldg. 7 Durham, NC 27713, Etats-Unis d’Amérique, en
contrefaçon des BREVETS DU CONTRAT étaient de la responsabilité du PRENEUR DE LICENCE car destinée à la défense des intérêts commerciaux du PRENEUR DE LICENCE et en conséquence les
parties ont souhaité appliquer ou amender LE CONTRAT DE LICENCE à cette fin.		On December 27, 2007, in furtherance of the provision regarding the protection of Licensee’s commercial interests as stated in section 7.3 of the Agreement, Licensor and Licensee, in mutual consultation, made the determination
that suing the company Precision Biosciences Inc (hereinafter the “Infringer”), with principal place of business at 104 T.W. Alexander Dr., Bldg. 7 Durham, NC 27713, USA for infringement of the Agreement Patents was Licensee’s
responsibility in order to protect said commercial interests, and consequently, the parties are willing to apply or amend the Agreement in that perspective.

			
		
	II est dès lors convenu ce qui suit entre les parties:		It has therefore been agreed as follows between the Parties:
	  
 Article 1:
		  
 Article 1

		
	Les mots en lettres capitales sont ceux définis dans LE CONTRAT DE LICENCE.		Capitalized words are defined as in the Agreement.
	  
 Article 2:
		  
 Article 2

		
	En application de l’article 7 du CONTRAT DE LICENCE, le DONNEUR DE LICENCE s’engage à coopérer avec LE PRENEUR DE LICENCE dans le but de déterminer les arguments juridiques, scientifiques ou relatifs
aux brevets utiles pour établir la contrefaçon et défendre la validité et la portée des BREVETS DU CONTRAT.		According to article 7 of the Agreement, Licensor shall undertake to cooperate with Licensee with a view to determining the legal, scientific, or patent arguments useful to establish the infringements and to defend the validity and
scope of the Agreement Patents.
		
	LE PRENEUR DE LICENCE poursuivra le CONTREFACTEUR en application des paragraphes 7.3, 7.4, 7.6 et 7.7 du CONTRAT DE LICENCE.		Licensee shall sue the Infringer according to sections 7.3, 7.4, 7.6 and 7.7 of the Agreement.
	  
 Article 3:
		  
 Article 3

		
	Toutes les dispositions CONTRAT DE LICENCE qui ne sont pas modifiés par le présent amendement restent inchangées.		All provisions of the Agreement that are not amended by the present amendment remain unchanged.
		
	Fait à Paris, le 26 février 2008		Done in Paris on February 26, 2008.
		
	Le DONNEUR DE LICENCE		Le PRENNEUR DE LICENCE
		
	The Licensor		The Licensee
		
	

		

	  
	  	  

	 Alice DAUTRY
 Directrice
Générale
		 Andre CHOULIKA
 Directeur
Général

		
	Président		Chief Executive Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00241-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00241-of-00352.parquet"}]]